scispace - formally typeset
G

Gordon H. Williams

Researcher at Brigham and Women's Hospital

Publications -  563
Citations -  39948

Gordon H. Williams is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Angiotensin II & Aldosterone. The author has an hindex of 88, co-authored 559 publications receiving 38048 citations. Previous affiliations of Gordon H. Williams include University of Sydney & University of Michigan.

Papers
More filters
Journal ArticleDOI

Selective Aldosterone Blockade with Eplerenone Reduces Albuminuria in Patients with Type 2 Diabetes

TL;DR: Both eplerenone treatment groups significantly reduced albuminuria from baseline as early as week 4, whereas placebo treatment (including enalapril) did not result in any significant decreases in UACR, and systolic BP decreased significantly in all treatment groups at all time points.
Journal ArticleDOI

Sustained Effectiveness of Converting-Enzyme Inhibition in Patients with Severe Congestive Heart Failure

TL;DR: It is concluded that captopril reduces afterload in advanced congestive heart failure and induces sustained improvements in clinical status and renal function.
Journal ArticleDOI

Captopril-induced Changes in Prostaglandin Production RELATIONSHIP TO VASCULAR RESPONSES IN NORMAL MAN

TL;DR: Changes in depressor prostaglandin production can better account for the hypotensive response to captopril, thereby extending to yet another vasoactive system an influence by this class of drugs and providing a new approach to dissecting the abnormality in the control of vascular tone in patients with hypertension.
Journal ArticleDOI

Reciprocal Influence of Salt Intake on Adrenal Glomerulosa and Renal Vascular Responses to Angiotensin II in Normal Man

TL;DR: Sodium intake reciprocally influences vascular and adrenal responses to A II: salt restriction blunts the vascular response and potentiates the adrenal's, a physiologically important influence in view of aldosterone's role in sodium conservation.
Journal ArticleDOI

Converting-enzyme inhibitors in the treatment of hypertension.

TL;DR: In 1982, Vidt and colleagues reviewed the pharmacokinetics, mechanisms of action, and therapeutic usefulness of captopril, the first of a new class of antihypertensives, converting-enzyme inhibitor, and found it to be of high therapeutic usefulness.